Nektar Therapeutics (NKTR) — Cash Flow-to-Debt Ratio
Nektar Therapeutics (NKTR) has a Cash Flow-to-Debt Ratio of -0.39x as of June 2026, meaning its operating cash flow of $-75.77 Million could theoretically repay 0% of its total liabilities ($192.01 Million) in one year. See financial agility of Nektar Therapeutics to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nektar Therapeutics Cash Flow-to-Debt Ratio (1994–2025)
Historical debt coverage capacity for Nektar Therapeutics across 32 annual periods. For the full cash flow conversion analysis, see Nektar Therapeutics cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Nektar Therapeutics (1994–2025)
Year-by-year debt coverage analysis for Nektar Therapeutics. Check Nektar Therapeutics (NKTR) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.09x | $-208.51 Million | $190.57 Million | ▼ -51.4% |
| 2024 | -0.72x | $-175.71 Million | $243.11 Million | ▼ -0.2% |
| 2023 | -0.72x | $-192.61 Million | $267.05 Million | ▲ +18.4% |
| 2022 | -0.88x | $-304.01 Million | $343.96 Million | ▲ +6.3% |
| 2021 | -0.94x | $-412.66 Million | $437.68 Million | ▼ -38.9% |
| 2020 | -0.68x | $-313.29 Million | $461.47 Million | ▼ -18.1% |
| 2019 | -0.57x | $-328.68 Million | $571.97 Million | ▼ -134.6% |
| 2018 | 1.66x | $718.21 Million | $432.60 Million | ▲ +969.3% |
| 2017 | -0.19x | $-80.41 Million | $421.04 Million | ▲ +21.5% |
| 2016 | -0.24x | $-117.02 Million | $480.75 Million | ▼ -65.1% |
| 2015 | -0.15x | $-73.08 Million | $495.63 Million | ▲ +57.9% |
| 2014 | -0.35x | $-142.01 Million | $405.29 Million | ▼ -376.9% |
| 2013 | -0.07x | $-38.53 Million | $524.43 Million | ▲ +74.5% |
| 2012 | -0.29x | $-129.76 Million | $450.77 Million | ▼ -3.4% |
| 2011 | -0.28x | $-113.74 Million | $408.74 Million | ▼ -114.4% |
| 2010 | -0.13x | $-55.87 Million | $430.56 Million | ▼ -254.5% |
| 2009 | 0.08x | $39.74 Million | $473.15 Million | ▲ +121.3% |
| 2008 | -0.39x | $-145.78 Million | $370.38 Million | ▼ -237.4% |
| 2007 | 0.29x | $146.30 Million | $510.66 Million | ▲ +267.2% |
| 2006 | -0.17x | $-92.72 Million | $541.12 Million | ▼ -16.8% |
| 2005 | -0.15x | $-78.00 Million | $531.74 Million | ▲ +47.9% |
| 2004 | -0.28x | $-78.14 Million | $277.58 Million | ▼ -67.2% |
| 2003 | -0.17x | $-76.20 Million | $452.60 Million | ▲ +10.2% |
| 2002 | -0.19x | $-74.97 Million | $399.87 Million | ▼ -46.6% |
| 2001 | -0.13x | $-50.77 Million | $396.93 Million | ▼ -25.9% |
| 2000 | -0.10x | $-35.74 Million | $351.66 Million | ▲ +7.1% |
| 1999 | -0.11x | $-15.33 Million | $140.18 Million | ▲ +89.4% |
| 1998 | -1.03x | $-19.22 Million | $18.61 Million | ▼ -570.2% |
| 1997 | 0.22x | $4.98 Million | $22.67 Million | ▲ +124.2% |
| 1996 | -0.91x | $-5.80 Million | $6.40 Million | ▲ +48.7% |
| 1995 | -1.77x | $-5.30 Million | $3.00 Million | ▲ +20.5% |
| 1994 | -2.22x | $-4.00 Million | $1.80 Million | — |